Loading
NASDAQHealthcareBiotechnology
Latest quote
$11.00
−$0.42 · -3.68%
MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction. The company's leading investigational therapy is AGENT-797. This product is an allogeneic, ready-to-use iNKT cell therapy, presently in Phase 1 clinical studies to assess its effectiveness against different forms of myeloma. Established in 2017, the company was previously known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. is headquartered in New York, New York, and operates as a subsidiary of Agenus Inc.
Previous close
$11.00
−$0.42 · -3.68%
After-hours
$11.15
+$0.15 · +1.36%
Oct 8, 7:30 PM ET
Regular session · ET · Market data may be delayed.
MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction. The company's leading investigational therapy is AGENT-797. This product is an allogeneic, ready-to-use iNKT cell therapy, presently in Phase 1 clinical studies to assess its effectiveness against different forms of myeloma. Established in 2017, the company was previously known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. is headquartered in New York, New York, and operates as a subsidiary of Agenus Inc.
Day range
Current $11.00
52-week range
Current $11.00
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
28
Expensive
Sentiment
54
Mixed
Risk
67
High Risk
Momentum
32
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction. The company's leading investigational therapy is AGENT-797. This product is an allogeneic, ready-to-use iNKT cell therapy, presently in Phase 1 clinical studies to assess its effectiveness against different forms of myeloma. Established in 2017, the company was previously known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. is headquartered in New York, New York, and operates as a subsidiary of Agenus Inc.
Day range
Current $11.00
52-week range
Current $11.00
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 181.75K USD | 215.44K USD | 204.62K USD | 121.75K USD | 77.96K USD |
| Gross profit | −181.75K USD | −215.44K USD | −204.62K USD | −121.75K USD | −77.96K USD |
| Research and development | 5.76M USD | 6.34M USD | 15.49M USD | 23.12M USD | 13.97M USD |
| Selling, general, and administrative | 6.55M USD | 4.1M USD | 7.43M USD | 7.71M USD | 4.56M USD |
| Operating expenses | 12.31M USD | 10.43M USD | 22.72M USD | 30.83M USD | 18.53M USD |
| Interest income | 180.25K USD | 172.57K USD | 463.26K USD | 253.32K USD | — |
| Interest expense | — | — | — | 253.32K USD | 2.43M USD |
| Depreciation and amortization | 181.75K USD | 215.44K USD | 204.62K USD | 121.75K USD | 77.96K USD |
| Operating income | −12.49M USD | −10.65M USD | −22.92M USD | −30.95M USD | −18.61M USD |
| Net income | −12.49M USD | −10.78M USD | −22.46M USD | −27.99M USD | −30.21M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$35.00
218.18% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jan 28, 2025 | 1:10 | — | — |
Effective Jan 28, 2025
1:10
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
iShares Micro-Cap ETFIWCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
